Tolerability of Favipiravir therapy in critically-ill patients with COVID-19: a report of 4 cases

J Med Virol. 2020 Sep 4. doi: 10.1002/jmv.26488. Online ahead of print.

ABSTRACT

Favipiravir (FVP) is an RNA polymerase inhibitor with broad anti-viral activity¹ . FVP is a pro-drug which is ribosylated and phosphorylated intracellularly to form the active metabolite and has a short half-life (2-5.5 hours) after oral administration² . This article is protected by copyright. All rights reserved.

PMID:32886358 | DOI:10.1002/jmv.26488